Test Kit for Dosage Determination for Safer Administration of Dichloroacetate

Technology #13485

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Peter W. Stacpoole
Taimour Y. Langaee
Managed By
April Kilburn
Assistant Director 352-392-8929
Patent Protection
US Patent 9,765,393

Treats Mitochondrial Diseases, Cancer and Other Conditions

This technology will enable the determination of a safe dosage of dichloroacetate (DCA), a chemical compound for potential treatment of various diseases, thus improving safety of DCA use. Cells in the human body, when significantly damaged, self destruct through a process known as apoptosis. However, in cancer tumors, cells fail to perform this process. DCA has been noted for restoring the apoptosis, a mitochondrial function, in cancer tumors and thus gained much attention. Nevertheless, DCA can also cause adverse side effects which ultimately aggravate the situation. Researchers at the University of Florida have developed a test kit that will allow individuals to be classified as relatively slow or fast metabolizers of DCA, and with that information an appropriate dosage of DCA can be determined, thereby minimizing adverse drug effects and permitting DCA to be used more safely.

Application

Test kit for use in clinical trials of DCA for treatment of mitochondrial diseases, cancer and other conditions

Advantages

  • Presents an inexpensive alternative to current treatments, offering a cost-effective alternative
  • Allows for DCA to be administered in more suitable dosages for each individual, permitting drug to be used with reduced side effects and increased safety
  • Provides broad market application since DCA can be used to treat cancer, mitochondrial diseases and other conditions, creating significant opportunity

Technology

Tests conducted at the University of Florida have determined that polymorphisms in the GSTz1/MAAI gene modify the kinetics of DCA and, consequently, the risk of adverse effects from the drug. GSTz1/MAAI haplotypes divide individuals into relatively fast and slow DCA metabolizers, each having a different reaction to DCA. With this knowledge, it is possible to adjust drug dosing and mitigate the risk of adverse side effects. Moreover, knowledge of the individual’s GSTz1/MAAI genotype and alleles can determine if that person is at a heightened risk for having adverse side effects to DCA —having a KGM or EGM allele means a heightened risk for adverse side effects, unless dosage adjustments are made. A testing kit would contain a first target substrate that can detect the presence of KGM allele and a second target substrate that can detect the presence of the EGM allele, positive controls for both KGM and EGM and optionally a test container, a sampling system, instruction for use, first and second targeting substrates, and the like.